Please login to the form below

Not currently logged in
Email:
Password:

Dry eye disease

This page shows the latest Dry eye disease news and features for those working in and with pharma, biotech and healthcare.

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe

Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Dry eye disease causes discomfort, stinging and blurry vision, and can significantly affect quality of life in some patients,

Latest news

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    Shire has agreed a licencing deal with Parion Sciences for a dry eye disease drug that bolsters its ophthalmic portfolio, a priority area for the Irish group. ... This is an opportunity to apply our knowledge and experience from ophthalmics and dry eye

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire's recently-approved dry eye disease drug Xiidra is now available in the US, throwing down a challenge to Allergan's rival therapy Restasis. ... Some analysts believe the product could actually benefit from the increased awareness of dry eye disease

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    FDA finally approves Shire’ s potential blockbuster Xiidra. Dry eye disease treatment wins US licence. ... adds. Dry eye disease is caused by a reduced ability to produce tears and is characterised by red, painful eyes and vulnerability to infections.

  • FDA deals a big blow to Shire's late-stage pipeline FDA deals a big blow to Shire's late-stage pipeline

    Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which has been tipped as a $1bn product. ... Dry eye disease is caused by a reduced ability to produce tears and is characterised by

  • Shire buys into eyecare specialist Shire buys into eyecare specialist

    Shire buys into eyecare specialist. Will complement its investigational dry eye drug lifitegrast. ... This acquisition further strengthens Shire's late-stage pipeline, and has a strategic fit with its investigational drug lifitegrast, which is in

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics